About Multiple Sclerosis Foundation



Home > Learn About Multiple Sclerosis > News > Ocrelizumab makes strong showing in OPERA studies

Ocrelizumab makes strong showing in OPERA studies

7/2/2015

Phase 3 study findings show ocrelizumab, created by Genentech, significantly reduced both relapses and disability progression in MS compared to Rebif® (interferon beta-1a). The studies also showed a significant reduction in the number of brain lesions.

Treatment with ocrelizumab significantly reduced the annualised relapse rate during a two-year period compared with interferon beta-1a, the primary endpoint in both studies. Ocrelizumab also significantly reduced the progression of clinical disability compared with interferon beta-1a, as measured by the Expanded Disability Status Scale. Additionally, treatment with ocrelizumab led to a significant reduction in the number of lesions in the brain compared with interferon beta-1a, as measured by MRI.

Overall, the incidence of adverse events associated with ocrelizumab was similar to interferon beta-1a in both studies; the most common adverse events were mild-to-moderate infusion-related reactions. The incidence of serious adverse events associated with ocrelizumab, including serious infections, was also similar to interferon beta-1a.

Further analyses of the OPERA studies are ongoing. Results from a Phase III study of ocrelizumab in people with primary progressive MS, a different form of MS, are expected later this year.



  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 

 

Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved

�